Pharmacology and potential role of selatogrel, a subcutaneous platelet P2Y12 receptor antagonist

Expert Opin Emerg Drugs. 2020 Mar;25(1):1-6. doi: 10.1080/14728214.2020.1729121. Epub 2020 Feb 17.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Coronary Syndrome / drug therapy
  • Blood Platelets / drug effects
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Humans
  • Injections, Subcutaneous
  • Organophosphonates / administration & dosage
  • Organophosphonates / pharmacology*
  • Organophosphonates / therapeutic use
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / pharmacology*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Purinergic P2Y Receptor Antagonists / administration & dosage
  • Purinergic P2Y Receptor Antagonists / pharmacology*
  • Purinergic P2Y Receptor Antagonists / therapeutic use
  • Pyrimidines / administration & dosage
  • Pyrimidines / pharmacology*
  • Pyrimidines / therapeutic use

Substances

  • Organophosphonates
  • Platelet Aggregation Inhibitors
  • Purinergic P2Y Receptor Antagonists
  • Pyrimidines
  • selatogrel